CONCERT PHARMACEUTICALS ANNOUNCES PRESENTATION OF CTP-543 THRIVE-AA1 PHASE 3 DATA IN ALOPECIA AREATA DURING LATE BREAKING SESSION AT EADV CONGRESS

MILAN - Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the presentation of data from its Phase 3 clinical trial, THRIVE-AA1.

The presentation highlights THRIVE-AA1 study results evaluating Concert's oral investigational medicine CTP-543 in adult patients with moderate to severe alopecia areata, an autoimmune disorder that results in patchy or complete scalp hair loss. The THRIVE-AA1 data are being presented by Brett King, M.D., Department of Dermatology, Yale University School of Medicine and clinical investigator of THRIVE-AA1, during the 31st European Academy of Dermatology and Venereology (EADV) Congress Late Breaking News Session.

In the THRIVE-AA1 study, significant improvements in scalp hair regrowth compared to placebo were achieved at 24 weeks for patients taking 8 mg twice-daily and 12 mg twice-daily doses of CTP-543, as previously disclosed in the positive topline results reported by Concert earlier this year. Treatment with CTP-543 was generally well tolerated. The EADV presentation includes new data from the THRIVE-AA1 study showing the ability of CTP-543 to achieve more stringent criteria for hair regrowth than the study's primary endpoint of absolute Severity of Alopecia Tool (SALT) score of 20 or less (meaning 20 percent or less scalp hair loss) at Week 24. Specifically, 21 percent and 35 percent of the patients in the CTP-543 8 mg twice-daily and 12 mg twice-daily dose groups, respectively, achieved a SALT score of 10 or less at Week 24, compared to 0 percent of patients in the placebo group (p